Mice deficient in TLR9 have been documented to be protected from HFD-induced liver steatosis and inflammation, thus pointing out the importance of the TLR-9 pathway in modulating inflammation in NASH [91,92,93]. Here, TLR9 is linked to metabolic dysfunction-associated steatohepatitis.